Acute Respiratory Distress Syndrome (ARDS)

Table of Contents

  1. Overview
  2. Epidemiology
  3. Pathophysiology
  4. Etiology and Risk Factors
  5. Clinical Presentation
  6. Diagnosis
  7. Treatment
  8. Complications
  9. Prognosis
  10. Prevention
  11. Recent Research
  12. References

1. Overview

Acute Respiratory Distress Syndrome (ARDS) is a life-threatening form of acute hypoxemic respiratory failure characterized by widespread alveolar damage, non-cardiogenic pulmonary edema, refractory hypoxemia, and reduced lung compliance. It represents the most severe manifestation of acute lung injury and carries substantial mortality, particularly in the intensive care unit (ICU) setting.

First described by Ashbaugh and colleagues in 1967, ARDS has undergone multiple definitional revisions over subsequent decades. The current standard — the Berlin Definition (2012) — classifies ARDS by severity based on the ratio of arterial oxygen partial pressure to the fraction of inspired oxygen (PaO2/FiO2), replacing the older American-European Consensus Conference (AECC) criteria. The Berlin Definition eliminated the term "acute lung injury" as a separate category and refined the timing, imaging, and oxygenation criteria to improve diagnostic reliability and prognostic stratification.

From a mechanistic standpoint, ARDS results from a dysregulated inflammatory cascade triggered by direct pulmonary insults or indirect systemic injuries. Massive cytokine release, neutrophil sequestration, alveolar epithelial and endothelial injury, and surfactant dysfunction culminate in alveolar flooding, collapse, and impaired gas exchange. The hallmark pathological lesion is diffuse alveolar damage (DAD), which progresses through distinct phases — exudative, proliferative, and fibrotic — each carrying distinct clinical and therapeutic implications.

Management has been transformed by the landmark ARDSNet ARMA trial demonstrating that low tidal volume ventilation (6 ml/kg ideal body weight) with plateau pressure limitation reduces mortality. Additional strategies including optimal PEEP titration, prone positioning, neuromuscular blockade, conservative fluid management, and in refractory cases, veno-venous extracorporeal membrane oxygenation (VV-ECMO), form the backbone of contemporary critical care.

2. Epidemiology

ARDS is a major global public health burden. Epidemiologic estimates vary substantially by case-finding methodology, diagnostic criteria applied, and clinical setting, but population-based studies from high-income countries provide consistent benchmarks.

3. Pathophysiology

Diffuse Alveolar Damage (DAD)

The hallmark histopathological lesion of ARDS is diffuse alveolar damage (DAD), a stereotyped injury response seen regardless of the precipitating cause. DAD is characterized by injury to both the alveolar epithelium (primarily type I pneumocytes) and the pulmonary capillary endothelium, leading to loss of the alveolocapillary barrier. The result is flooding of alveolar spaces with protein-rich edema fluid, cellular debris, and inflammatory cells.

DAD progresses through three overlapping histological phases:

Exudative Phase (Days 1–7)

The exudative phase dominates the first week of illness and is characterized by:

Proliferative Phase (Days 7–21)

If the patient survives the exudative phase, the proliferative phase commences, characterized by attempts at lung repair:

Fibrotic Phase (Weeks 3–4 onward)

In a subset of patients — particularly those with prolonged severe ARDS — extensive fibroproliferation leads to the fibrotic phase:

Mechanical Consequences: Baby Lung Concept

CT imaging of ARDS lungs reveals that consolidated and atelectatic regions are predominantly dependent (posterior in supine patients), while aerated regions are nondependent. The concept of the "baby lung," introduced by Gattinoni, refers to the relatively small volume of normally aerated lung available for ventilation — typically 200–500 mL. Ventilating this small compartment with standard tidal volumes (10–12 ml/kg) generates dangerously high regional pressures and stresses, causing ventilator-induced lung injury (VILI) through cyclic overdistension (volutrauma) and repetitive alveolar collapse and reopening (atelectrauma).

4. Etiology and Risk Factors

ARDS etiologies are broadly categorized as direct (pulmonary) or indirect (extrapulmonary) lung injuries:

Direct Pulmonary Causes

Indirect Extrapulmonary Causes

Host Risk Factors

5. Clinical Presentation

ARDS typically presents within 72 hours of the precipitating insult, though onset can be as rapid as hours after aspiration or as delayed as 5–7 days in sepsis-associated cases. The clinical presentation reflects progressive respiratory failure superimposed on the underlying condition.

Symptoms

Signs

Laboratory and Bedside Findings

6. Diagnosis

Berlin Definition (2012)

The Berlin Definition, developed by an expert panel under the auspices of the European Society of Intensive Care Medicine and endorsed by ATS and SCCM, replaced the AECC criteria (1994) and defines ARDS by four elements:

  1. Timing: Onset within 1 week of a known clinical insult or new or worsening respiratory symptoms.
  2. Chest imaging: Bilateral opacities on chest radiograph or CT not fully explained by effusions, lobar/lung collapse, or pulmonary nodules.
  3. Origin of edema: Respiratory failure not fully explained by cardiac failure or fluid overload. Objective assessment (echocardiography) required if no risk factor present.
  4. Oxygenation: Classified by PaO2/FiO2 ratio measured on a minimum PEEP/CPAP of 5 cmH2O.

Severity Classification by PaO2/FiO2 Ratio

Note: PaO2/FiO2 ratios should ideally be measured after stabilization on the ventilator setting (typically 30 minutes to 2 hours after initiation or change in settings). SpO2/FiO2 (S/F ratio) can serve as a noninvasive surrogate when arterial blood gas is unavailable; an S/F ratio of ≤315 corresponds approximately to PaO2/FiO2 ≤300.

Differential Diagnosis

The following conditions must be excluded or distinguished from ARDS:

Ancillary Investigations

7. Treatment

Lung-Protective Mechanical Ventilation — ARDSNet Protocol

The cornerstone of ARDS management is lung-protective ventilation (LPV), established by the ARDSNet ARMA trial (NEJM, 2000). This landmark multicenter RCT randomized 861 patients to tidal volume (Vt) of 6 ml/kg ideal body weight (IBW) versus 12 ml/kg IBW and demonstrated a 22% relative reduction in 28-day mortality (31% vs. 39.8%, p=0.007).

Ideal Body Weight Calculation (ARDSNet):

ARDSNet ARMA Ventilator Protocol Key Parameters:

PEEP Titration

PEEP (positive end-expiratory pressure) prevents end-expiratory alveolar collapse (atelectrauma), recruits collapsed alveoli, and improves oxygenation. Optimal PEEP minimizes atelectrauma without causing overdistension of aerated units.

ARDSNet Lower PEEP / Higher FiO2 Table:

ARDSNet Higher PEEP / Lower FiO2 Table (ALVEOLI study):

The ALVEOLI, LOV, and EXPRESS trials found no mortality benefit of higher versus lower PEEP strategies when analyzed by intention to treat, though subgroup analyses suggest benefit in moderate-to-severe ARDS. Recruitment maneuvers (e.g., 40 cmH2O sustained inflation for 40 seconds, or PEEP titration via decremental PEEP trial after full recruitment) may improve oxygenation acutely but the ART trial demonstrated potential harm (increased 28-day mortality) with aggressive recruitment maneuver strategies in unselected patients.

Alternative PEEP titration methods include:

Prone Positioning

Prone positioning redistributes lung stress more homogeneously, recruits dependent atelectatic regions, reduces ventral overdistension, and improves cardiac preload in certain physiologic conditions. The landmark PROSEVA trial (Guerin et al., NEJM 2013) demonstrated dramatic survival benefit of early prone positioning in severe ARDS:

Current guidelines (SSC, ATS) strongly recommend prone positioning for moderate-to-severe ARDS (PaO2/FiO2 <150 mmHg). Contraindications include spinal instability, open abdomen, facial/pelvic fractures, elevated intracranial pressure, and hemodynamic instability refractory to vasopressors.

Neuromuscular Blockade (NMB)

The ACURASYS trial (Papazian et al., NEJM 2010) reported improved 90-day survival with 48-hour cisatracurium infusion in severe ARDS (PaO2/FiO2 <150 mmHg). The proposed mechanisms included reduced patient-ventilator asynchrony, improved lung protection through elimination of spontaneous effort-induced lung injury (P-SILI), and anti-inflammatory effects of cisatracurium specifically.

However, the larger ROSE trial (NEJM 2019) — performed in a context of lighter sedation protocols — found no mortality benefit of routine early NMB versus a strategy of light sedation without NMB (42.5% vs. 42.8% in-hospital mortality). Current guidance recommends NMB be considered in severe ARDS when:

Cisatracurium is preferred for its Hofmann elimination (not dependent on renal or hepatic clearance) and its potential direct anti-inflammatory properties. Critical illness myopathy and neuropathy risk must be weighed against potential benefit; ICU-acquired weakness is more prevalent with prolonged NMB use.

Conservative Fluid Strategy

The FACTT trial (ARDSNet, NEJM 2006) compared liberal versus conservative fluid management in ARDS. Conservative strategy (targeting CVP 4–6 mmHg, PAOP 8–12 mmHg with diuresis or fluid restriction) resulted in:

Conservative fluid management is now standard practice, using diuretics (furosemide) or continuous renal replacement therapy (CRRT) to achieve negative or neutral fluid balance, provided hemodynamic stability is maintained. Serum albumin supplementation (combined with furosemide) may improve diuresis in hypoalbuminemic patients.

Corticosteroids

The role of corticosteroids in ARDS remains nuanced and context-dependent:

Extracorporeal Membrane Oxygenation (ECMO)

Veno-venous ECMO (VV-ECMO) provides extracorporeal gas exchange in patients with refractory severe ARDS unresponsive to optimized conventional management. VV-ECMO allows "ultraprotective ventilation" — further reducing Vt (3–4 ml/kg IBW) and Pplat (<25 cmH2O) to minimize VILI while the ECMO circuit handles CO2 removal and oxygenation.

Key evidence:

Current practice: VV-ECMO is offered at ECMO-capable centers for severe ARDS (PaO2/FiO2 <80 mmHg on FiO2 1.0 or pH <7.25 with PaCO2 >60 mmHg) failing prone positioning and optimized conventional ventilation. Absolute contraindications include irreversible underlying disease incompatible with recovery, unresolved major bleeding, prolonged high-pressure ventilation (>7 days at Pplat >30 cmH2O), severe immunosuppression, and significant pre-existing end-organ dysfunction.

High-Flow Nasal Cannula (HFNC) and Non-Invasive Ventilation (NIV)

In mild ARDS or early hypoxemic respiratory failure, HFNC (flows up to 60 L/min, FiO2 up to 1.0) reduces intubation rates and 90-day mortality compared to conventional oxygen in selected patients (FLORALI trial). The ROX index (SpO2/FiO2 ratio divided by respiratory rate) >4.88 at 12 hours predicts successful HFNC and avoidance of intubation.

NIV (BiPAP) may be used in mild-to-moderate ARDS but failure rates are high in moderate-to-severe disease, and delayed intubation in failing NIV is associated with worse outcomes. Awake prone positioning during HFNC or NIV (particularly in COVID-19) may improve oxygenation and reduce intubation rates, though mortality benefit remains uncertain.

Treatment of Underlying Cause

Identifying and aggressively treating the precipitating cause is essential and parallels ventilatory management:

8. Complications

Ventilator-Induced Lung Injury (VILI)

VILI encompasses multiple mechanisms of mechanical ventilation-related lung injury occurring even in the absence of ARDS:

Barotrauma and Air Leak Syndromes

Pneumothorax occurs in 5–10% of mechanically ventilated ARDS patients and is immediately life-threatening when tension physiology develops. Clinical hallmarks of tension pneumothorax include sudden hemodynamic deterioration, absent breath sounds unilaterally, tracheal deviation, and elevated peak airway pressures. Immediate needle decompression followed by chest tube thoracostomy is required. Pneumothorax should be distinguished from massive consolidation on portable CXR, requiring CT confirmation when hemodynamic stability permits.

Ventilator-Associated Pneumonia (VAP)

VAP occurs in 10–25% of intubated ARDS patients, typically after 48 hours of mechanical ventilation. Common pathogens include Pseudomonas aeruginosa, Acinetobacter baumannii, and methicillin-resistant Staphylococcus aureus (MRSA). VAP prolongs mechanical ventilation by a median of 5 days and increases ICU mortality. Prevention bundles include head-of-bed elevation (30–45°), oral decontamination with chlorhexidine, sedation minimization, and daily spontaneous awakening and breathing trials.

Pulmonary Hypertension and Acute Cor Pulmonale (ACP)

ACP complicates 20–25% of moderate-to-severe ARDS. Hypoxic vasoconstriction, hypercapnia-induced vasoconstriction, microvascular thrombosis, and mechanical compression by PEEP increase pulmonary vascular resistance. Right ventricular (RV) dilation, interventricular septal shift (D-sign on echo), and reduced RV ejection fraction characterize ACP. ACP is associated with significantly increased ICU mortality (OR ~2.0). Management includes optimization of PEEP to minimize pulmonary vascular resistance, avoidance of excessive hypercapnia, inhaled pulmonary vasodilators (nitric oxide, prostacyclin), and prone positioning (which unloads the RV).

Multi-Organ Dysfunction Syndrome (MODS)

ARDS-associated systemic inflammation and hypoxia contribute to dysfunction of kidneys (acute kidney injury requiring RRT in 30–55%), liver (cholestatic hepatopathy), brain (ICU-associated delirium and cognitive dysfunction), gut (ileus, mucosal barrier failure), and adrenal glands (relative adrenal insufficiency). MODS is the most common cause of death in ARDS, accounting for over 80% of in-hospital mortality.

Post-Intensive Care Syndrome (PICS) and Long-Term Sequelae

ARDS survivors face substantial long-term morbidity beyond discharge:

9. Prognosis

ARDS mortality has declined significantly from the 50–70% reported in early series (1970s–1990s) to approximately 30–45% in the modern era, attributable largely to lung-protective ventilation strategies, prone positioning, and improved sepsis management.

Mortality by Severity (Berlin Definition)

These figures from the Berlin Definition validation cohort (ARDS Definition Task Force, JAMA 2012) reflect outcomes in the pre-PROSEVA era; contemporary severe ARDS mortality with optimal care including prone positioning may be lower in specialized centers.

Predictors of Mortality

Causes of Death

The majority of ARDS deaths are attributable to multi-organ dysfunction rather than refractory hypoxemia. In the ARDSNet ARMA trial, only 16% of deaths were from respiratory failure alone; the remainder resulted from sepsis, cardiovascular collapse, and multiple organ failure. This underscores the importance of source control, hemodynamic optimization, and prevention of secondary complications.

10. Prevention

Primary prevention targets reduction of ARDS incidence in at-risk populations:

11. Recent Research

The field of ARDS research has advanced substantially, with several areas of active investigation:

ARDS Phenotyping — Precision Medicine Approaches

Latent class analysis has identified two reproducible ARDS phenotypes with distinct biological signatures and treatment responses:

This phenotypic heterogeneity may explain the failure of numerous ARDS pharmacotherapy trials (statins, activated protein C, beta-agonists, omega-3 fatty acids) in unselected populations. Adaptive platform trial designs (REMAP-CAP) that incorporate phenotypic stratification represent the next frontier in ARDS therapeutics.

Driving Pressure as a Ventilator Target

The 2015 retrospective analysis by Amato et al. (NEJM) demonstrated that driving pressure (Pplat − PEEP) was more strongly associated with survival than either Pplat or PEEP alone, across multiple RCT datasets. Driving pressure ≤15 cmH2O appears to be the key mechanical threshold. Prospective trials specifically targeting driving pressure reduction as the primary ventilator management goal are ongoing.

Ultra-Protective Ventilation with Extracorporeal CO2 Removal (ECCO2R)

Low-flow ECCO2R devices enable tidal volume reduction below 6 ml/kg IBW (to 3–4 ml/kg) without hypercapnia by removing CO2 extracorporeally. The REST trial (McNamee et al., JAMA 2021) found no mortality benefit of very low Vt (3 ml/kg) ventilation with ECCO2R versus standard LPV and signal toward harm, including more bleeding events in the ECCO2R arm. Ultra-protective ventilation via ECCO2R requires further investigation with refined patient selection.

Awake Prone Positioning (APP)

Several RCTs during the COVID-19 pandemic investigated APP in non-intubated patients receiving HFNC or NIV. The PROFIT trial and meta-analyses suggest that APP reduces intubation rates in selected patients with COVID-19-associated hypoxemic respiratory failure, though benefits in non-COVID ARDS remain less established. Duration of 8–16 hours per day of APP appears necessary for meaningful benefit.

Mesenchymal Stromal Cell (MSC) Therapy

MSCs exert immunomodulatory, anti-inflammatory, and reparative effects in preclinical ARDS models. Phase I/II trials (START-1, START-2) demonstrated safety and potential signals of efficacy. The ongoing Phase IIb START trial (NCT03818854) is evaluating MSC efficacy in ARDS with mortality as a secondary endpoint.

Keratinocyte Growth Factor (KGF) / Palifermin

KGF stimulates type II pneumocyte proliferation and enhances alveolar fluid clearance in preclinical models. The Phase II KARE trial found that KGF did not improve outcomes and was potentially harmful in ARDS, highlighting the challenge of translating preclinical biology into effective clinical interventions.

Biomarker-Guided Treatment

The SMART-ARDS adaptive platform trial and other biomarker-enrichment approaches are testing whether phenotyping at the bedside using readily available plasma markers (IL-8, TNFR1, protein C, PAI-1) can guide treatment allocation — matching patients to therapies they are most likely to benefit from, rather than applying uniform treatments across a heterogeneous syndrome.

12. References

  1. ARDS Definition Task Force; Ranieri VM, Rubenfeld GD, Thompson BT, et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA. 2012;307(23):2526–2533. doi:10.1001/jama.2012.5669
  2. Acute Respiratory Distress Syndrome Network; Brower RG, Matthay MA, Morris A, et al. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med. 2000;342(18):1301–1308. doi:10.1056/NEJM200005043421801
  3. Guérin C, Reignier J, Richard JC, et al; PROSEVA Study Group. Prone positioning in severe acute respiratory distress syndrome. N Engl J Med. 2013;368(23):2159–2168. doi:10.1056/NEJMoa1214103
  4. Papazian L, Forel JM, Gacouin A, et al; ACURASYS Study Investigators. Neuromuscular blockers in early acute respiratory distress syndrome. N Engl J Med. 2010;363(12):1107–1116. doi:10.1056/NEJMoa1005372
  5. National Heart, Lung, and Blood Institute PETAL Clinical Trials Network; Moss M, Huang DT, Brower RG, et al. Early neuromuscular blockade in the acute respiratory distress syndrome. N Engl J Med. 2019;380(21):1997–2008. doi:10.1056/NEJMoa1901686
  6. Wiedemann HP, Wheeler AP, Bernard GR, et al; National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network. Comparison of two fluid-management strategies in acute lung injury. N Engl J Med. 2006;354(24):2564–2575. doi:10.1056/NEJMoa062200
  7. Combes A, Hajage D, Capellier G, et al; EOLIA Trial Group, REVA, and ECMONet. Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome. N Engl J Med. 2018;378(21):1965–1975. doi:10.1056/NEJMoa1800385
  8. Amato MBP, Meade MO, Slutsky AS, et al. Driving pressure and survival in the acute respiratory distress syndrome. N Engl J Med. 2015;372(8):747–755. doi:10.1056/NEJMsa1410639
  9. Bellani G, Laffey JG, Pham T, et al; LUNG SAFE Investigators; ESICM Trials Group. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA. 2016;315(8):788–800. doi:10.1001/jama.2016.0291
  10. Herridge MS, Tansey CM, Matté A, et al; Canadian Critical Care Trials Group. Functional disability 5 years after acute respiratory distress syndrome. N Engl J Med. 2011;364(14):1293–1304. doi:10.1056/NEJMoa1011802
  11. Calfee CS, Delucchi K, Parsons PE, et al; NHLBI ARDS Network. Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials. Lancet Respir Med. 2014;2(8):611–620. doi:10.1016/S2213-2600(14)70097-9
  12. Peek GJ, Mugford M, Tiruvoipati R, et al; CESAR trial collaboration. Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial. Lancet. 2009;374(9698):1351–1363. doi:10.1016/S0140-6736(09)61069-2
  13. Frat JP, Thille AW, Mercat A, et al; FLORALI Study Group; REVA Network. High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. N Engl J Med. 2015;372(23):2185–2196. doi:10.1056/NEJMoa1503326
  14. Gattinoni L, Chiumello D, Rossi S. COVID-19 pneumonia: ARDS or not? Crit Care. 2020;24(1):154. doi:10.1186/s13054-020-02880-z
  15. RECOVERY Collaborative Group; Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384(8):693–704. doi:10.1056/NEJMoa2021436
  16. McNamee JJ, Gillies MA, Barrett NA, et al; REST Investigators. Effect of lower tidal volume ventilation facilitated by extracorporeal carbon dioxide removal vs standard care ventilation on 90-day mortality in patients with acute hypoxemic respiratory failure: the REST randomized clinical trial. JAMA. 2021;326(11):1013–1023. doi:10.1001/jama.2021.13520
  17. Guo Z, Sun H, Li Z. Advances in research of adult ARDS clinical subphenotypes. J Clin Med. 2022;11(14):4188. doi:10.3390/jcm11144188
  18. Sweeney RM, McAuley DF. Acute respiratory distress syndrome. Lancet. 2016;388(10058):2416–2430. doi:10.1016/S0140-6736(16)00578-X

Back to Table of Contents